Infliximab, a chimeric anti-TNFα monoclonal antibody, has been demonstrated to be an effective therapy for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and other autoimmune diseases. The gene discussed is TNF; the disease is ankylosing spondylitis.